%PDF-1.4
%
54 0 obj
<>
endobj
51 0 obj
<>
endobj
91 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-15T09:15:38Z
2024-03-29T04:13:48-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T04:13:48-07:00
application/pdf
Heather
201240 suppl
uuid:f3176e96-1dd1-11b2-0a00-a60927edca00
uuid:f3176e99-1dd1-11b2-0a00-380000000000
endstream
endobj
40 0 obj
<>
endobj
41 0 obj
<>
endobj
55 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
113 0 obj
[117 0 R]
endobj
114 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(fibromyalgia. Rheumatology 1999;38:355-61.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ. )17.7 (The longterm outcomes of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis: )17.7 (W)79.9 (ork disability: )54.8 (A)-220.1 (prospective 18 year study of 823)]TJ
0 -1.25 TD
[(patients. J Rheumatol 1998;25:2108-1)36.8 (17.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (W)79.9 (olfe F)79.7 (, Zwillich SH. )17.7 (The long-term outcomes of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis: )54.8 (A)-220.1 (23-year prospective, longitudinal study of total joint)]TJ
T*
(replacement and its predictors in 1600 patients with rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 1998;41:1072-82.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (W)79.9 (olfe F)79.7 (, Sharp JT)73.9 (. Radiographic outcome of recent-onset)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis: )54.8 (A)-220.1 (19-year study of radiographic progression.)]TJ
T*
(Arthritis Rheum 1998;41:1571-82.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (W)79.9 (olfe F)79.7 (. Data collection and utilization: a methodology for clinical)]TJ
2.175 -1.25 Td
[(practice and clinical research. In: )17.7 (W)79.9 (olfe F)79.7 (, Pincus )17.7 (T)74 (, editors.)]TJ
T*
(Rheumatoid arthritis: pathogenesis, assessment, outcome, and)Tj
T*
[(treatment. New )36.8 (Y)99.8 (ork: Marcel Dekker; 1994:463-514.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, Kraines RG, Holman HR. Measurement of)]TJ
2.175 -1.25 Td
[(patient outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (W)79.9 (olfe F)79.7 (, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW)91.7 (, Fries)]TJ
2.175 -1.25 Td
[(JF)79.7 (. )17.7 (The clinical value of the Stanford Health )54.8 (Assessment)]TJ
T*
(Questionnaire Functional Disability Index in patients with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1988;15:1480-8.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Hawley DJ, )17.7 (W)79.9 (olfe F)79.7 (. Depression is not more common in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis: a 10 year longitudinal study of 6,608)Tj
T*
(rheumatic disease patients. J Rheumatol 1993; 20:2025-31.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (deV)110.8 (ellis RF)79.7 (, Callahan LF)79.7 (. )54.8 (A)-220.1 (brief measure of helplessness in)]TJ
2.175 -1.25 Td
[(rheumatic disease \321 )17.7 (The Helplessness Subscale of the)]TJ
T*
[(Rheumatology )54.8 (Attitudes Index. J Rheumatol 1993;20:866-9.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Decker JL, McShane DJ, Esdaile JM, et al. Dictionary of the)]TJ
2.175 -1.25 Td
[(rheumatic diseases: )17.7 (V)128.9 (ol. I: Signs and symptoms. New )36.8 (Y)99.8 (ork:)]TJ
T*
[(Contact )54.8 (Associates International; 1982.)]TJ
30.825 36.25 Td
[(22.)-875.1 (W)79.9 (olfe F)79.7 (. Comparative usefulness of C-reactive protein and erythro-)]TJ
2.175 -1.25 Td
(cyte sedimentation rate in patients with rheumatoid arthritis. )Tj
T*
(J Rheumatol 1997;24:1477-85.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (W)79.9 (olfe F)79.7 (,)-0.1 ( Michaud K. )17.7 (The clinical and research significance of the)]TJ
2.175 -1.25 Td
(erythrocyte sedimentation rate. J Rheumatol 1994;21:1227-37.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (W)79.9 (olfe F)79.7 (, Cathey MA, Roberts FK. )17.7 (The latex test revisited \321)]TJ
2.175 -1.25 Td
(rheumatoid factor testing in 8,287 rheumatic disease patients.)Tj
T*
(Arthritis Rheum 1991;34:951-60.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Steinber)17.7 (g D, Colla P)110.7 (.)-0.1 ( CAR)59.7 (T)49.9 (:)0.1 ( )17.7 (T)35 (ree-structured non-parametric data)]TJ
2.175 -1.25 Td
(analysis. San Diego, CA: Salford Systems; 1995.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Breiman L, Friedman J, Olshen R, Stone C. Classification and)]TJ
2.175 -1.25 Td
[(regression trees. Pacific Grove: )17.7 (W)79.9 (adsworth; 1984.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Pincus )17.7 (T)74 (, Summey JA, Soraci SA)-220.2 (Jr)39.7 (, )17.7 (W)79.9 (allston KA, Hummon NP)110.7 (.)]TJ
2.175 -1.25 Td
(Assessment of patient satisfaction in activities of daily living using)Tj
T*
[(a modified Stanford Health )54.8 (Assessment Questionnaire. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1983;26:1346-53.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875.1 (Pincus )17.7 (T)74 (, Swearingen C, )17.7 (W)79.9 (olfe F)79.7 (.)-0.1 ( )17.7 (T)69.9 (oward a multidimensional)]TJ
2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire \(MDHAQ\) \321 )54.8 (Assessment of)]TJ
T*
(advanced activities of daily living and psychological status in the)Tj
T*
[(patient-friendly health assessment questionnaire format. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:2220-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (W)79.9 (olfe F)79.7 (.)-0.1 ( )54.8 (A)-220.1 (brief health status instrument: CLINHAQ [abstract].)]TJ
2.175 -1.25 Td
(Arthritis Rheum 1989;32 Suppl:S99. )Tj
-2.175 -1.25 Td
[(30.)-875.1 (W)79.9 (olfe F)79.7 (, O\325Dell JR, Kavanaugh )54.8 (A, )17.7 (W)39.8 (ilske K, Pincus )17.7 (T)74 (. Evaluating)]TJ
2.175 -1.25 Td
(severity and status in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:1453-62.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(W)91.9 (olfe, et al: Evaluation of RA)-257.3 (in clinic)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1717)Tj
ET
0 0 0 0 k
/GS0 gs
100.72 59.08 407.5 -10.83 re
f*
0.5 w
100.72 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
34 0 obj
<>stream
8;Z\7M[mTX#iu#8OP`noi/X+l\SN/t0%9$sni3:bWf>#j60.if]l2MWr:>+/ogt.>
q[1S9:sFgk&gkV81Zk:p^s%_(n]Z\;W=?'`?XM6Z^r7O(KQ[es]dgilof!cTk'W`C
AjdeToOb)R$,W;RQ7Tc)6(N+kQEQ;+B,N\)msp["l:D^%9HR?`IOc_^!:c-Z%!*!B
QB?0"=+S!GTN3*o8#6il>T?qsqE$!RTHl4*DZY4=p]),9`Dds++5h*,>$sD6W1qfW
$4lQ,9MEDeBsE=aQhDp-#ROiTl[F^H-50qTN:qEK_,IMP`WXZ:#$rGqeN
2B%QEUX
endstream
endobj
38 0 obj
[/Indexed/DeviceRGB 255 37 0 R]
endobj
37 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
61 0 obj
<>
endobj
57 0 obj
<>
endobj
78 0 obj
<>
endobj
96 0 obj
<>
endobj
58 0 obj
<>
endobj
70 0 obj
<>stream
HUiPSY~Kŧ`P^;heAmmpEhY"D%@ !$H1*"Ҹhb62c[3JUcyL35UnsT}☳kWϊ eSE,c}pv;`'9O}4˕8NDKPگ_ee+zßM>uTms
X.PHE)rff̼~!.d B&B!d̚D4C,|P&f9^̈dL<#' ⥻N&T.+2L*&>=iXʈ8YfL$b?Xa0w
ž 0'`
%.VaK=ľƲ0=fw;7>p|*?{xz4yz=NP88cbWēZ[exO6?fxn{r?ͤI)S)
4 YvZ,OJ3(qy&"I@1a0[3[[LX)SmxCpv::5vNM B:ZDW{[.tz`G1lzwkQZ.!.Sf\}'/(^.dZoBd>h2uE_Čj){
8h&Ė*U;
ѹܭz9%r ,5}އOogȊ_&T[,1TwixYԲLFdFGrTCp'q8Pgd9rd,QnIU'ɿ*U]z
!"Q~btF:E!R,/V{U{LU/[Y_F
az%gkS4!aRmP?p]d}ؗУdX(՜mh%s
V9MJPer&$y~ ol]@P>L%RV_\nYE*JS^W< Tn>dsxE6M.X_PKkW-숽]KC{
&